Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16639-16648

  Malaguarnera, Giulia ^a   Giordano, Maria ^b   Nunnari, Giuseppe ^c   Bertino, Gaetano ^b   Malaguarnera, Michele ^a  

^a Section of Pharmacology and Biochemistry   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c GARIBALDI HOSPITAL   (Italy)

Author keywords

Alcoholic liver disease; Bacterial translocation; Dysbiosis; Endotoxin; Gut microbiota; Prebiotics; Probiotics; Synbiotic

Indexed keywords

ANTIBIOTIC AGENT; ENDOTOXIN; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADAPTIVE IMMUNITY; ALCOHOL ABSTINENCE; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; DYSBIOSIS; ENDOTOXEMIA; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INTESTINE; LIVER; LIVER DISEASES, ALCOHOLIC; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; LIVER; LIVER DISEASES, ALCOHOLIC; PREBIOTICS; PROBIOTICS; SYNBIOTICS;

EID: 84912064085     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16639     Document Type: Article

References (118)

1. Lieber CS. Aetiology and pathogenesis of alcoholic liver disease. Baillieres Clin Gastroenterol 1993; 7: 581-608 [PMID: 8219401 DOI: 10.1016/0950-3528(93)90003-6]
2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teer-awattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223-2233 [PMID: 19560604 DOI: 10.1016/S0140-6736(09)60746-7]
3. Lieber CS. Hyperuricemia induced by alcohol. Arthritis Rheum 1965; 8: 786-798 [PMID: 5859552 DOI: 10.1002/ art.1780080442]
4. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-990 [PMID: 7475591 DOI: 10.1016/S0140-6736(95)91685-7]
5. Bode JC, Bode C, Heidelbach R, Dürr HK, Martini GA. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984; 31: 30-34 [PMID: 6698486]
6. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002; 88 Suppl 1: S39-S49 [PMID: 12215180 DOI: 10.1079/BJN2002628]
7. Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun 2013; 46: 66-73 [PMID: 24075647 DOI: 10.1016/ j.jaut.2013.07.001]
8. Gramenzi A, Caputo F, Biselli M, Kuria F, Loggi E, Andre-one P, Bernardi M. Review article: alcoholic liver disease-pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006; 24: 1151-1161 [PMID: 17014574 DOI: 10.1111/j.1365-2036.2006.03110.x]
9. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol 2000; 32:113-128 [PMID: 10728799 DOI: 10.1016/50168-8278(00)80420-1]
10. Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 2010; 391: 1249-1264 [PMID: 20868231 DOI: 10.1515/bc.2010.137]
11. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141:1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
12. Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275: G605-G611 [PMID: 9756487]
13. Hoek JB, Pastorino JC. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002; 27: 63-68 [PMID: 12062639 DOI: 10.1016/S0741-8329(02)00215-X]
14. Tsukamoto H, Takei Y, McClain CJ, Joshi-Barve S, Hill D, Schmidt J, Deaciuc I, Barve S, Colell A, Garcia-Ruiz C, Kaplowitz N, Fernandez-Checa JC, Yokoyama H, Okamura Y, Nakamura Y, Ishii H, Chawla RK, Barve S, Joshi-Barve S, Watson W, Nelson W, Lin M, Ohata M, Motomura K, Enomoto N, Ikejima K, Kitamura T, Oide H, Hirose M, Bradford BU, Rivera CA, Kono H, Peter S, Yamashina S, Konno A, Ishikawa M, Shimizu H, Sato N, Thurman R. How is the liver primed or sensitized for alcoholic liver disease? Alcohol Clin Exp Res 2001; 25: 171S-181S [PMID: 11391068 DOI: 10.1111/j.1530-0277.2001.tb02393.x]
15. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609 [PMID: 23055155 DOI: 10.1002/hep.26093]
16. Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17: 575-592 [PMID: 12828956 DOI: 10.1016/51521-6918(03)00034-9]
17. Visapää JP, Tillonen J, Salaspuro M. Microbes and mucosa in the regulation of intracolonic acetaldehyde concentration during ethanol challenge. Alcohol Alcohol 2002; 37: 322-326 [PMID: 12107032 DOI: 10.1093/alcalc/37.4.322]
18. Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health 2006; 29: 245-254 [PMID: 17718403]
19. Vonlaufen A, Wilson JS, Pirola RC, Apte MV. Role of alcohol metabolism in chronic pancreatitis. Alcohol Res Health 2007; 30: 48-54 [PMID: 17718401]
20. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 2007; 30: 5-13 [PMID: 17718394]
21. Seitz HK, Oneta CM. Gastrointestinal alcohol dehydrogenase. Nutr Rev 1998; 56: 52-60 [PMID: 9529900 DOI: 10.1111/ j.1753-4887.1998.tb01692.x]
22. Nosova T, Jokelainen K, Kaihovaara P, Heine R, Jousimies-Somer H, Salaspuro M. Characteristics of aldehyde dehydrogenases of certain aerobic bacteria representing human colonic flora. Alcohol Alcohol 1998; 33: 273-280 [PMID: 9632053 DOI: 10.1093/oxfordjournals.alcalc.a008391]
23. Kwon HJ, Won YS, Park O, Chang B, Duryee MJ, Thiele GE, Matsumoto A, Singh S, Abdelmegeed MA, Song BJ, Kawamoto T, Vasiliou V, Thiele GM, Gao B. Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice. Hepatology 2014; 60:146-157 [PMID: 24492981 DOI: 10.1002/hep.27036]
24. Lieber CS. Liver disease of the alcoholic: pathogenesis and metabolic complications. Ala J Med Sci 1975; 12: 355-360 [PMID: 1200320]
25. Atkinson KJ, Rao RK. Role of protein tyrosine phosphorylation in acetaldehyde-induced disruption of epithelial tight junctions. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1280-G1288 [PMID: 11352822]
26. Seth A, Basuroy S, Sheth P, Rao RK. L-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Am J Physiol Gastrointest Liver Physiol 2004; 287: G510-G517 [PMID: 15331350 DOI: 10.1152/ajpgi.00058.2004]
27. Sheth P, Seth A, Atkinson KJ, Gheyi T, Kale G, Giorgianni F, Desiderio DM, Li C, Naren A, Rao R. Acetaldehyde dissociates the PTPIB-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J 2007; 402: 291-300 [PMID: 17087658 DOI: 10.1042/BJ20060665]
28. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004; 113: 427-437 [PMID: 15554920]
29. Takahashi S, Mendelsohn ME. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem 2003; 278: 30821-30827 [PMID: 12799359 DOI: 10.1074/jbc. M304471200]
30. Vallance BA, Dijkstra G, Qiu B, van der Waaij LA, van Goor H, Jansen PL, Mashimo H, Collins SM. Relative contributions of NOS isoforms during experimental colitis: endothelialderived NOS maintains mucosal integrity. Am J Physiol Gastrointest Liver Physiol 2004; 287: G865-G874 [PMID: 15217783 DOI: 10.1152/ajpgi.00187.2004]
31. Kimura H, Nakajima T, Kagawa K, Deguchi T, Kakusui M, Katagishi T, Okanoue T, Kashima K, Ashihara T. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver 1998; 18:14-19 [PMID: 9548262 DOI: 10.1111/j.1600-0676.1998.tb00121.x]
32. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 1998; 17: 91-106 [PMID: 9544425 DOI: 10.123/A:]
33. Banan A, Fields JZ, Decker H, Zhang Y, Keshavarzian A. Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. J Pharmacol Exp Ther 2000; 294: 997-1008 [PMID: 10945852]
34. Banan A, Keshavarzian A, Zhang L, Shaikh M, Forsyth CB, Tang Y, Fields JZ. NF-kappaB activation as a key mechanism in ethanol-induced disruption of the F-actin cytoskeleton and monolayer barrier integrity in intestinal epithelium. Alcohol 2007; 41: 447-460 [PMID: 17869053 DOI: 10.1016/ j.alcohol.2007.07.003]
35. Banan A, Farhadi A, Fields JZ, Zhang LJ, Shaikh M, Keshavarzian A. The delta-isoform of protein kinase C causes inducible nitric-oxide synthase and nitric oxide up-regulation: key mechanism for oxidant-induced carbonylation, nitration, and disassembly of the microtubule cytoskeleton and hyperpermeability of barrier of intestinal epithelia. J Pharmacol Exp Ther 2003; 305: 482-494 [PMID: 12606598 DOI: 10.1124/ jpet.102.047308]
36. Banan A, Zhang LJ, Shaikh M, Fields JZ, Farhadi A, Keshavarzian A. Inhibition of oxidant-induced nuclear factorkappaB activation and inhibitory-kappaBalpha degradation and instability of F-actin cytoskeletal dynamics and barrier function by epidermal growth factor: key role of phospholipase-gamma isoform. J Pharmacol Exp Ther 2004; 309: 356-368 [PMID: 14724221 DOI: 10.1124/jpet.103.062232]
37. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999; 69:1035S-1045S [PMID: 10232646]
38. Saavedra JM, Tschernia A. Human studies with probiotics and prebiotics: clinical implications. Br J Nutr 2002; 87 Suppl 2: S241-S246 [PMID: 12088524 DOI: 10.1079/BJN/2002543]
39. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80 [PMID: 19026645 DOI: 10.1053/j.gastro.2008.10.080]
40. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519 [PMID: 12583961 DOI: 10.1016/ S0140-6736(03)12489-0]
41. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco G, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011; 43: 431-438 [PMID: 21163715 DOI: 10.1016/j.dld.2010.10.015]
42. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56: 1283-1292 [PMID: 22326468 DOI: 10.1016/j.jhep.2012.01.019]
43. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, Gobejishvili L, Joshi-Barve S, Ayvaz T, Petrosino J, Kong M, Barker D, McClain G, Barve S. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 2013; 8: e53028 [PMID: 23326376 DOI: 10.1371/journal.pone.0053028]
44. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302: G966-G978 [PMID: 22241860 DOI: 10.1152/ajpgi.00380.2011]
45. Fadl AA, Sha J, Klimpel GR, Olano JP, Niesel DW, Chopra AK. Murein lipoprotein is a critical outer membrane component involved in Salmonella enterica serovar typhimurium systemic infection. Infect Immun 2005; 73: 1081-1096 [PMID: 15664952 DOI: 10.1128/IAI.73.2.1081-1096.2005]
46. Fleming S, Toratani S, Shea-Donohue T, Kashiwabara Y, Vogel SN, Metcalf ES. Pro- and anti-inflammatory gene expression in the murine small intestine and liver after chronic exposure to alcohol. Alcohol Clin Exp Res 2001; 25: 579-589 [PMID: 11329499 DOI: 10.HH/j.1530-0277.2001.tb02253.x]
47. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009; 43: 163-172 [PMID: 19251117 DOI: 10.1016/ j.alcohol.2008.12.009]
48. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 2010; 16: 403-410 [PMID: 20101763 DOI: 10.3748/wjg.v16. i4.403]
49. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004; 286: G367-G376 [PMID: 14766535 DOI: 10.1152/ajpgi.00173.2003]
50. Rao RK, Seth A, Sheth P. Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 286: G881-G884 [PMID: 15132946 DOI: 10.1152/ ajpgi.00006.2004]
51. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial over-growth. Dig Dis Sci 2008; 53: 1443-1454 [PMID: 17990113 DOI: 10.1007/s10620-007-0065-1]
52. Sachdev AH, Pimentel M. Gastrointestinal bacterial over-growth: pathogenesis and clinical significance. Ther Adv Chronic Dis 2013; 4: 223-231 [PMID: 23997926 DOI: 10.1177/2 040622313496126]
53. Bouhnik Y, Alain S, Attar A, Flourié B, Raskine L, SansonLe Pors MJ, Rambaud JC. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94:1327-1331 [PMID: 10235214 DOI: 10.1111/j.1572-0241.1999.01016.x]
54. Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007; 25: 1271-1281 [PMID: 17509095 DOI: 10.1111/ j.1365-2036.2007.03313.x]
55. Nelson S, Kolls JK. Alcohol, host defence and society. Nat Rev Immunol 2002; 2: 205-209 [PMID: 11913071 DOI: 10.1038/ nri744]
56. Jerrells TR, Peritt D, Marietta G, Eckardt MJ. Mechanisms of suppression of cellular immunity induced by ethanol. Alcohol Clin Exp Res 1989; 13: 490-493 [PMID: 2679202 DOI: 10.1111/j.1530-0277.1989.tb00363.x]
57. Sibley D, Jerrells TR. Alcohol consumption by C57BL/6 mice is associated with depletion of lymphoid cells from the gut-associated lymphoid tissues and altered resistance to oral infections with Salmonella typhimurium. J Infect Dis 2000; 182: 482-489 [PMID: 10915079 DOI: 10.1086/315728]
58. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008; 24: 4-10 [PMID: 18043225 DOI: 10.1097/MOG.0b013e3282f2b0e8]
59. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311:1-16 [PMID: 17048703 DOI: 10.1007/3-540-32636-7-1]
60. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-825 [PMID: 16410796 DOI: 10.1038/sj.cdd.4401850]
61. Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res 2013; 43: 139-146 [PMID: 22970713 DOI: 10.HH/j.1872-034X.2012.01088.x.]
62. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433 [PMID: 1698311 DOI: 10.1126/science.1698311]
63. Wright SD, Tobias PS, Ulevitch RJ, Ramos RA. Lipopolysac-charide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med 1989; 170: 1231-1241 [PMID: 2477488 DOI: 10.1084/ jem.170.4.1231]
64. Oliva J, Bardag-Gorce F, Li J, French BA, French SW. S-adenosylmethionine prevents the up regulation of Toll-like receptor (TLR) signaling caused by chronic ethanol feeding in rats. Exp Mol Pathol 2011; 90: 239-243 [PMID: 21276439 DOI: 10.1016/j.yexmp.2011.01.005]
65. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012; 590: 447-458 [PMID: 22124143 DOI: 10.1113/ jphysiol.2011.219691]
66. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13:1324-1332 [PMID: 17952090 DOI: 10.1038/nm1663]
67. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009; 1: 949-964 [PMID: 20563267 DOI: 10.2217/ imt.09.70]
68. Inokuchi S, Tsukamoto H, Park E, Liu ZX, Brenner DA, Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res 2011; 35: 1509-1518 [PMID: 21463341 DOI: 10.1111/j.1530-0277.2011.01487.x]
69. Blanco AM, Perez-Arago A, Fernandez-Lizarbe S, Guerri C. Ethanol mimics ligand-mediated activation and endocytosis of IL-1RI/TLR4 receptors via lipid rafts caveolae in astroglial cells. J Neurochem 2008; 106: 625-639 [PMID: 18419766 DOI: 10.HH/j.1471-4159.2008.05425.x.]
70. Blanco AM, Vallés SL, Pascual M, Guerri C. Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. J Immunol 2005; 175: 6893-6899 [PMID: 16272348 DOI: 10.4049/jimmunol.175.10.6893]
71. Shen Z, Ajmo JM, Rogers CQ, Liang X, Le L, Murr MM, Peng Y, You M. Role of SIRTI in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1047-G1053 [PMID: 19299582 DOI: 10.1152/ajpgi.00016.2009]
72. Parés A, Caballería J, Bruguera M, Torres M, Rodés J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2: 33-42 [PMID: 3950362 DOI: 10.1016/S0168-8278(86)80006-X]
73. Mathurin P, Deng QG, Keshavarzian A, Choudhary S, Holmes EW, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 2000; 32: 1008-1017 [PMID: 11050051 DOI: 10.1053/jhep.2000.19621]
74. Parlesak A, Schäfer C, Schütz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000; 32: 742-747 [PMID: 10845660 DOI: 10.1016/50168-8278(00)80242-1]
75. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R, Sartor RB, Swanson C, Turner JR. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical conse-quences: summary of a symposium. Alcohol 2008; 42: 349-361 [PMID: 18504085 DOI: 10.1016/j.alcohol.2008.03.131]
76. Järveläinen HA, Fang C, Ingelman-Sundberg M, Lindros KO. Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology 1999; 29: 1503-1510 [PMID: 10216135 DOI: 10.1002/hep.510290508]
77. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008; 48: 983-992 [PMID: 18395289 DOI: 10.1016/j.jhep.2008.01.035]
78. Singh VV, Toskes PP. Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Curr Treat Options Gastroenterol 2004; 7: 19-28 [PMID: 14723835 DOI: 10.1007/ s11938-004-0022-4]
79. Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010; 24: 943-59, viii-ix [PMID: 20937459 DOI: 10.1016/j.idc.2010.07.007]
80. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081 [PMID: 20335583 DOI: 10.1056/NEJMoa0907893]
81. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 17-25 [PMID: 19881343 DOI: 10.1097/ MOG.0b013e328333dc8d]
82. Rabenstein T, Fromm MF, Zolk O. [Rifaximin-a nonresorbable antibiotic with many indications in gastroenterology]. Z Gastroenterol 2011; 49: 211-224 [PMID: 21225568 DOI: 10.1055/s-0029-1245705]
83. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus Chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-556 [PMID: 10792117 DOI: 10.1046/j.1365-2036.2000.00751.x]
84. Cummings JH, Macfarlane GT. Gastrointestinal effects of prebiotics. Br J Nutr 2002; 87 Suppl 2: S145-S151 [PMID: 12088511 DOI: 10.1079/BJN/2002530]
85. Ouwehand AC, Derrien M, de Vos W, Tiihonen K, Rautonen N. Prebiotics and other microbial substrates for gut function-ality. Curr Opin Biotechnol 2005; 16: 212-217 [PMID: 15831389 DOI: 10.1016/j.copbio.2005.01.007]
86. Yan AW, Fonts DE, Brandi J, Stärkei P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105 [PMID: 21254165 DOI: 10.1002/hep.24018]
87. Roberfroid MB. Inulin-type fructans: functional food ingredients. J Nutr 2007; 137: 2493S-2502S [PMID: 17951492]
88. Watzl B. Consumption of vegetables and fruits and risk of breast cancer. JAMA 2005; 293: 2209-210; author reply 2210 [PMID: 15886371 DOI: 10.1001/jama.293.18.2209-b]
89. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007; 137: 830S-837S [PMID: 17311983]
90. Gibson GR. Prebiotics as gut microflora management tools. J Clin Gastroenterol 2008; 42 Suppl 2: S75-S79 [PMID: 18542038 DOI: 10.1097/MCG.0b013e31815ed097]
91. Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of entero-pathogenic Escherichia coli to tissue culture cells. Infect Immun 2006; 74: 6920-6928 [PMID: 16982832 DOI: 10.1128/ IAI.01030-06]
92. Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol Cell Biol 2000; 78: 80-88 [PMID: 10651933 DOI: 10.1046/j.1440-1711.2000.00886. x]
93. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90-97 [PMID: 1905394]
94. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995; 13: 310-312 [PMID: 7631519 DOI: 10.1016/0264-410X(95)93319-5]
95. Tsai CC, Hsih HY, Chiu HH, Lai YY, Liu JH, Yu B, Tsen HY. Antagonistic activity against Salmonella infection in vitro and in vivo for two Lactobacillus strains from swine and poultry. Int J Food Microbiol 2005; 102: 185-194 [PMID: 15992617 DOI: 10.1016/j.ijfoodmicro.2004.12.014]
96. Younts-Dahl SM, Osborn GD, Galyean ML, Rivera JD, Loneragan GH, Brashears MM. Reduction of Escherichia coli 0157 in finishing beef cattle by various doses of Lactobacillus acidophilus in direct-fed microbiais. J Food Prot 2005; 68: 6-10 [PMID: 15690797]
97. Peterson RE, Klopfenstein TJ, Moxley RA, Erickson GE, Hinkley S, Rogan D, Smith DR. Efficacy of dose regimen and observation of herd immunity from a vaccine against Escherichia coli 0157: H7 for feedlot cattle. J Food Prot 2007; 70: 2561-2567 [PMID: 18044435]
98. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr 2006; 95: 1177-1184 [PMID: 16768842 DOI: 10.1079/BJN20051681]
99. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-247 [PMID: 8171045 DOI: 10.3181/00379727-205-43703]
100. Griffiths EA, Duffy LC, Schanbacher FL, Qiao H, Dryja D, Leavens A, Rossman J, Rich G, Dirienzo D, Ogra PL. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci 2004; 49: 579-589 [PMID: 15185861 DOI: 10.1023/B:]
101. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95: S2-S4 [PMID: 10634218 DOI: 10.1016/ S0002-9270(99)00806-0]
102. Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Pennisi G, Li Volti G, Galvano F. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010; 22: 199-206 [PMID: 19730107 DOI: 10.1097/MEG.0b013e328330a8d3]
103. Malaguarnera G, Leggio F, Vacante M, Motta M, Giordano M, Bondi A, Basile F, Mastrojeni S, Mistretta A, Malaguarnera M, Toscano MA, Salmeri M. Probiotics in the gastrointestinal diseases of the elderly. J Nutr Health Aging 2012; 16: 402-410 [PMID: 22499466 DOI: 10.1007/ s12603-011-0357-1]
104. Kanauchi O, Fujiyama Y, Mitsuyama K, Araki Y, Ishii T, Nakamura T, Hitomi Y, Agata K, Saiki T, Andoh A, Toyonaga A, Bamba T. Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med 1999; 3:175-179 [PMID: 9917526]
105. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157: H7-induced changes in epithelial barrier function. Infect Immun 2008; 76: 1340-1348 [PMID: 18227169 DOI: 10.1128/IAI.00778-07]
106. O'Sullivan DJ. Genomics can advance the potential for probiotic cultures to improve liver and overall health. Curr Pharm Des 2008; 14:1376-1381 [PMID: 18537660 DOI: 10.2174 /138161208784480234]
107. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs 1997; 53: 930-942 [PMID: 9179525 DOI: 10.2165/00003495-199753060-00003]
108. Foster KJ, Lin S, Turck CJ. Current and emerging strategies for treating hepatic encephalopathy. Crit Care Nurs Clin North Am 2010; 22: 341-350 [PMID: 20691385 DOI: 10.1016/ j.ccell.2010.04.007]
109. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125:1401-1412 [PMID: 7782892]
110. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone G, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f]
111. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553 [PMID: 21901256 DOI: 10.1007/s10620-011-1887-4]
112. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267 [PMID: 22674330 DOI: 10.1126/ science.1223813]
113. Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, Guarino A. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004; 20: 813-819 [PMID: 15379842 DOI: 10.1111/j.1365-2036.2004.02174.x]
114. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988-997 [PMID: 12801956 DOI: 10.1136/gut.52.7.988]
115. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620-1633 [PMID: 15168372 DOI: 10.1053/j.gastro.2004.03.024]
116. Versalovic J. Probiotics: intestinal gatekeeping, immunomodulation, and hepatic injury. Hepatology 2007; 46: 618-621 [PMID: 17879361 DOI: 10.1002/hep.21916]
117. Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, Nardone G. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22: 471-476 [PMID: 22546554 DOI: 10.1016/ j.numecd.2012.02.007]
118. Frazier TH, Stocker AM, Kershner NA, Marsano LS, Mc-Clain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol 2011; 4: 63-81 [PMID: 21317995 DOI: 10.1177/17 56283X10378925]